Leqembi (lecanemab) is a new Alzheimer's disease treatment option from Biogen/Eisai. The drug has a unique mechanism of action that is thought to slow down the progression of the disease by neutralizing and eliminating soluble, toxic amyloid-beta (Aβ) aggregates (protofibrils) that may contribute to the neurodegenerative process.
After two months on the market, ZoomRx asked neurologists and psychiatrists about their first impressions and expressions of the drug. Out of the 30 surveyed HCPs, 16 were aware of the drug, and only 6 of them said they are highly likely to use the product.
The open-ended responses showed that HCPs have mixed impressions of the drug. Some of them were hopeful and saw the drug as a promising treatment for Alzheimer's disease, particularly for early-onset cases. They appreciated the novel mechanism of action and the potential to slow down the disease's progression. Others were more cautious and wanted to see more clinical data before prescribing it.
“The data doesn't suggest much improvement in my patients with Alzheimer's disease.”
“In general I am less apt to prescribe newly approved treatments until they've been on the market for long.”
“I would want to see some of my experienced colleagues experiences with this medication. When it is less expensive and has more insurance coverage I certainly see the potential for this medication to be used.”
One concern that several HCPs mentioned was the administration of the drug through intravenous infusion every two weeks. Some HCPs felt that their patients may be hesitant to undergo such treatment, while others thought that the inconvenience may outweigh the potential benefits of the drug.
Overall, HCPs are aware of Leqembi but are not entirely convinced of its efficacy and safety. Some felt that the drug had a better side effect and efficacy profile than Aducanumab, while others were unsure and wanted more clinical data.
